Forsythoside B Mitigates Monocrotaline-Induced Pulmonary Arterial Hypertension via Blocking the NF-κB Signaling Pathway to Attenuate Vascular Remodeling

References

• Ruopp NF, Cockrill BA. Diagnosis and treatment of pulmonary arterial hypertension: a review. JAMA. 2022;327(14):1379–1391. doi:10.1001/jama.2022.4402
   PubMed Web of Science ®Google Scholar
• Jiang Y, Song S, Liu J, et al. Epigenetic regulation of programmed cell death in hypoxia-induced pulmonary arterial hypertension. Front Immunol. 2023;14:1206452. doi:10.3389/fimmu.2023.1206452
   PubMed Web of Science ®Google Scholar
• Naeije R, Richter MJ, Rubin LJ. The physiological basis of pulmonary arterial hypertension. Eur Respir J. 2022;59(6):2102334. doi:10.1183/13993003.02334-2021
   PubMed Web of Science ®Google Scholar
• Olsson KM, Corte TJ, Kamp JC, et al. Pulmonary hypertension associated with lung disease: new insights into pathomechanisms, diagnosis, and management. Lancet Respir Med. 2023;11(9):820–835. doi:10.1016/s2213-2600(23)00259-x
   PubMed Web of Science ®Google Scholar
• Hassoun PM. Pulmonary Arterial Hypertension. N Engl J Med. 2021;385(25):2361–2376. doi:10.1056/NEJMra2000348
   PubMed Web of Science ®Google Scholar
• Hurdman J, Condliffe R, Elliot CA, et al. ASPIRE registry: assessing the spectrum of pulmonary hypertension identified at a REferral centre. Eur Respir J. 2012;39(4):945–955. doi:10.1183/09031936.00078411
   PubMed Web of Science ®Google Scholar
• Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. Signal Transduct Target Ther. 2017;2(17023):17023. doi:10.1038/sigtrans.2017.23
   PubMedGoogle Scholar
• Gong Y, Kong B, Shuai W, Chen T, Zhang JJ, Huang H. USP38 regulates inflammatory cardiac remodeling after myocardial infarction. Clin Sci. 2023;137(21):1665–1681. doi:10.1042/cs20230728
   Web of Science ®Google Scholar
• Wu S, Zhou Y, Liang J, et al. Upregulation of NF-κB by USP24 aggravates ferroptosis in diabetic cardiomyopathy. Free Radic Biol Med. 2024;210:352–366. doi:10.1016/j.freeradbiomed.2023.11.032
   PubMed Web of Science ®Google Scholar
• Parpaleix A, Amsellem V, Houssaini A, et al. Role of interleukin-1 receptor 1/MyD88 signalling in the development and progression of pulmonary hypertension. Eur Respir J. 2016;48(2):470–483. doi:10.1183/13993003.01448-2015
   PubMed Web of Science ®Google Scholar
• Krzyżewska A, Baranowska-Kuczko M, Jastrząb A, Kasacka I, Kozłowska H. Cannabidiol improves antioxidant capacity and reduces inflammation in the lungs of rats with monocrotaline-induced pulmonary hypertension. Molecules. 2022;27(10):3327. doi:10.3390/molecules27103327
   PubMed Web of Science ®Google Scholar
• Hu Y, Chi L, Kuebler WM, Goldenberg NM. Perivascular inflammation in pulmonary arterial hypertension. Cells. 2020;9(11):2338. doi:10.3390/cells9112338
   PubMed Web of Science ®Google Scholar
• Sawada H, Mitani Y, Maruyama J, et al. A nuclear factor-kappaB inhibitor pyrrolidine dithiocarbamate ameliorates pulmonary hypertension in rats. Chest. 2007;132(4):1265–1274. doi:10.1378/chest.06-2243
   PubMed Web of Science ®Google Scholar
• Chen M, Ding Z, Zhang F, et al. A20 attenuates hypoxia-induced pulmonary arterial hypertension by inhibiting NF-κB activation and pulmonary artery smooth muscle cell proliferation. Exp Cell Res. 2020;390(2):111982. doi:10.1016/j.yexcr.2020.111982
   PubMed Web of Science ®Google Scholar
• Wang Z, Xia Q, Liu X, et al. Phytochemistry, pharmacology, quality control and future research of Forsythia suspensa (Thunb.) Vahl: a review. J Ethnopharmacol. 2018;210:318–339. doi:10.1016/j.jep.2017.08.040
   PubMed Web of Science ®Google Scholar
• Jiang WL, Yong X, Zhang SP, Zhu HB, Jian H. Forsythoside B protects against experimental sepsis by modulating inflammatory factors. Phytother Res. 2012;26(7):981–987. doi:10.1002/ptr.3668
   PubMed Web of Science ®Google Scholar
• Liu JX, Li X, Yan FG, et al. Protective effect of forsythoside B against lipopolysaccharide-induced acute lung injury by attenuating the TLR4/NF-κB pathway. Int Immunopharmacol. 2019;66:336–346. doi:10.1016/j.intimp.2018.11.033
   PubMed Web of Science ®Google Scholar
• Kong F, Jiang X, Wang R, Zhai S, Zhang Y, Wang D. Forsythoside B attenuates memory impairment and neuroinflammation via inhibition on NF-κB signaling in Alzheimer’s disease. J Neuroinflammation. 2020;17(1):305. doi:10.1186/s12974-020-01967-2
   PubMed Web of Science ®Google Scholar
• Jiang WL, Fu FH, Xu BM, Tian JW, Zhu HB, Jian H. Cardioprotection with forsythoside B in rat myocardial ischemia-reperfusion injury: relation to inflammation response. Phytomedicine. 2010;17(8–9):635–639. doi:10.1016/j.phymed.2009.10.017
   PubMed Web of Science ®Google Scholar
• Yu M, Wu X, Peng L, et al. Inhibition of Bruton’s tyrosine kinase alleviates monocrotaline-induced pulmonary arterial hypertension by modulating macrophage polarization. Oxid Med Cell Longev. 2022;2022:6526036. doi:10.1155/2022/6526036
   PubMed Web of Science ®Google Scholar
• Zhu Z, Godana D, Li A, et al. Echocardiographic assessment of right ventricular function in experimental pulmonary hypertension. Pulm Circ. 2019;9(2):2045894019841987. doi:10.1177/2045894019841987
   Web of Science ®Google Scholar
• Yared K, Noseworthy P, Weyman AE, McCabe E, Picard MH, Baggish AL. Pulmonary artery acceleration time provides an accurate estimate of systolic pulmonary arterial pressure during transthoracic echocardiography. J Am Soc Echocardiogr. 2011;24(6):687–692. doi:10.1016/j.echo.2011.03.008
   PubMed Web of Science ®Google Scholar
• Lan C, Fang G, Qiu C, Li X, Yang F, Yang Y. Inhibition of DYRK1A attenuates vascular remodeling in pulmonary arterial hypertension via suppressing STAT3/Pim-1/NFAT pathway. Clin Exp Hypertens. 2024;46(1):2297642. doi:10.1080/10641963.2023.2297642
   PubMed Web of Science ®Google Scholar
• Guo J, Yang ZC, Liu Y. Attenuating pulmonary hypertension by protecting the integrity of glycocalyx in rats model of pulmonary artery hypertension. Inflammation. 2019;42(6):1951–1956. doi:10.1007/s10753-019-01055-5
   PubMed Web of Science ®Google Scholar
• Gao L, Fan Y, Hao Y, et al. Cysteine-rich 61 (Cyr61) upregulated in pulmonary arterial hypertension promotes the proliferation of pulmonary artery smooth muscle cells. Int J Med Sci. 2017;14(9):820–828. doi:10.7150/ijms.19282
   PubMed Web of Science ®Google Scholar
• Mendes-Ferreira P, Maia-Rocha C, Adão R, et al. Neuregulin-1 improves right ventricular function and attenuates experimental pulmonary arterial hypertension. Cardiovasc Res. 2016;109(1):44–54. doi:10.1093/cvr/cvv244
   PubMed Web of Science ®Google Scholar
• Yang JM, Zhou R, Zhang M, Tan HR, Yu JQ. Betaine attenuates monocrotaline-induced pulmonary arterial hypertension in rats via inhibiting inflammatory response. Molecules. 2018;23(6). doi:10.3390/molecules23061274
   Web of Science ®Google Scholar
• Sheikh AQ, Lighthouse JK, Greif DM. Recapitulation of developing artery muscularization in pulmonary hypertension. Cell Rep. 2014;6(5):809–817. doi:10.1016/j.celrep.2014.01.042
   PubMed Web of Science ®Google Scholar
• Tang L, Cai Q, Wang X, et al. Canagliflozin ameliorates hypobaric hypoxia-induced pulmonary arterial hypertension by inhibiting pulmonary arterial smooth muscle cell proliferation. Clin Exp Hypertens. 2023;45(1):2278205. doi:10.1080/10641963.2023.2278205
   PubMed Web of Science ®Google Scholar
• Tang BL, Liu Y, Zhang JL, Lu ML, Wang HX. Ginsenoside Rg1 ameliorates hypoxia-induced pulmonary arterial hypertension by inhibiting endothelial-to-mesenchymal transition and inflammation by regulating CCN1. Biomed Pharmacother. 2023;164:114920. doi:10.1016/j.biopha.2023.114920
   PubMed Web of Science ®Google Scholar
• Dougherty EJ, Chen LY, Awad KS, et al. Inflammation and DKK1-induced AKT activation contribute to endothelial dysfunction following NR2F2 loss. Am J Physiol Lung Cell Mol Physiol. 2023;324(6):L783–l798. doi:10.1152/ajplung.00171.2022
   PubMed Web of Science ®Google Scholar
• Mahler GJ, Farrar EJ, Butcher JT. Inflammatory cytokines promote mesenchymal transformation in embryonic and adult valve endothelial cells. Arterioscler Thromb Vasc Biol. 2013;33(1):121–130. doi:10.1161/atvbaha.112.300504
   PubMed Web of Science ®Google Scholar
• Li Y, Ren W, Wang X, et al. MicroRNA-150 relieves vascular remodeling and fibrosis in hypoxia-induced pulmonary hypertension. Biomed Pharmacother. 2019;109:1740–1749. doi:10.1016/j.biopha.2018.11.058
   PubMed Web of Science ®Google Scholar
• Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M. NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol. 1999;19(4):2690–2698. doi:10.1128/mcb.19.4.2690
   PubMed Web of Science ®Google Scholar
• Chen S, Yan D, Qiu A. The role of macrophages in pulmonary hypertension: pathogenesis and targeting. Int Immunopharmacol. 2020;88:106934. doi:10.1016/j.intimp.2020.106934
   PubMed Web of Science ®Google Scholar
• Lajoie AC, Lauzière G, Lega JC, et al. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respir Med. 2016;4(4):291–305. doi:10.1016/s2213-2600(16)00027-8
   PubMed Web of Science ®Google Scholar
• Chin KM, Sitbon O, Doelberg M, et al. Three- versus two-drug therapy for patients with newly diagnosed pulmonary arterial hypertension. J Am Coll Cardiol. 2021;78(14):1393–1403. doi:10.1016/j.jacc.2021.07.057
   PubMed Web of Science ®Google Scholar
• Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809–818. doi:10.1056/NEJMoa1213917
   PubMed Web of Science ®Google Scholar
• Mirhadi E, Roufogalis BD, Banach M, Barati M, Sahebkar A. Resveratrol: mechanistic and therapeutic perspectives in pulmonary arterial hypertension. Pharmacol Res. 2021;163:105287. doi:10.1016/j.phrs.2020.105287
   PubMed Web of Science ®Google Scholar
• Davidson KW, Barry MJ, Mangione CM, et al. Aspirin use to prevent cardiovascular disease: us preventive services task force recommendation statement. JAMA. 2022;327(16):1577–1584. doi:10.1001/jama.2022.4983
   PubMed Web of Science ®Google Scholar
• Feng W, Wang J, Yan X, et al. Paclitaxel alleviates monocrotaline-induced pulmonary arterial hypertension via inhibition of FoxO1-mediated autophagy. Naunyn Schmiedebergs Arch Pharmacol. 2019;392(5):605–613. doi:10.1007/s00210-019-01615-4
   PubMed Web of Science ®Google Scholar
• Beik A, Najafipour H, Joukar S, Rajabi S, Iranpour M, Kordestani Z. Perillyl alcohol suppresses monocrotaline-induced pulmonary arterial hypertension in rats via anti-remodeling, anti-oxidant, and anti-inflammatory effects. Clin Exp Hypertens. 2021;43(3):270–280. doi:10.1080/10641963.2020.1860080
   PubMed Web of Science ®Google Scholar
• Nazemiyeh H, Rahman MM, Gibbons S, et al. Assessment of the antibacterial activity of phenylethanoid glycosides from Phlomis lanceolata against multiple-drug-resistant strains of Staphylococcus aureus. J Nat Med. 2008;62(1):91–95. doi:10.1007/s11418-007-0194-z
   PubMed Web of Science ®Google Scholar
• Li Y, Yang Y, Kang X, et al. Study on the anti-inflammatory effects of Callicarpa nudiflora based on the spectrum-effect relationship. Front Pharmacol. 2021;12:806808. doi:10.3389/fphar.2021.806808
   PubMed Web of Science ®Google Scholar
• Yoo TK, Jeong WT, Kim JG, et al. UPLC-ESI-Q-TOF-MS-based metabolite profiling, antioxidant and anti-inflammatory properties of different organ extracts of Abeliophyllum distichum. Antioxidants. 2021;10(1):70. doi:10.3390/antiox10010070
   Web of Science ®Google Scholar
• Lau EMT, Giannoulatou E, Celermajer DS, Humbert M. Epidemiology and treatment of pulmonary arterial hypertension. Nat Rev Cardiol. 2017;14(10):603–614. doi:10.1038/nrcardio.2017.84
   PubMed Web of Science ®Google Scholar
• Thompson AAR, Lawrie A. Targeting vascular remodeling to treat pulmonary arterial hypertension. Trends Mol Med. 2017;23(1):31–45. doi:10.1016/j.molmed.2016.11.005
   PubMed Web of Science ®Google Scholar
• Smith ER, Wang JQ, Yang DH, Xu XX. Paclitaxel resistance related to nuclear envelope structural sturdiness. Drug Resist Updat. 2022;65:100881. doi:10.1016/j.drup.2022.100881
   PubMed Web of Science ®Google Scholar
• Dai Z, Zhu MM, Peng Y, et al. Therapeutic targeting of vascular remodeling and right heart failure in pulmonary arterial hypertension with a HIF-2α inhibitor. Am J Respir Crit Care Med. 2018;198(11):1423–1434. doi:10.1164/rccm.201710-2079OC
   PubMed Web of Science ®Google Scholar
• Pullamsetti SS, Mamazhakypov A, Weissmann N, Seeger W, Savai R. Hypoxia-inducible factor signaling in pulmonary hypertension. J Clin Invest. 2020;130(11):5638–5651. doi:10.1172/jci137558
   PubMed Web of Science ®Google Scholar
• Schermuly RT, Ghofrani HA, Wilkins MR, Grimminger F. Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol. 2011;8(8):443–455. doi:10.1038/nrcardio.2011.87
   PubMed Web of Science ®Google Scholar
• Li X, Zhang X, Leathers R, et al. Notch3 signaling promotes the development of pulmonary arterial hypertension. Nat Med. 2009;15(11):1289–1297. doi:10.1038/nm.2021
   PubMed Web of Science ®Google Scholar
• Hong J, Arneson D, Umar S, et al. Single-cell study of two rat models of pulmonary arterial hypertension reveals connections to human pathobiology and drug repositioning. Am J Respir Crit Care Med. 2021;203(8):1006–1022. doi:10.1164/rccm.202006-2169OC
   PubMed Web of Science ®Google Scholar
• Soon E, Holmes AM, Treacy CM, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation. 2010;122(9):920–927. doi:10.1161/circulationaha.109.933762
   PubMed Web of Science ®Google Scholar
• Savai R, Pullamsetti SS, Kolbe J, et al. Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012;186(9):897–908. doi:10.1164/rccm.201202-0335OC
   PubMed Web of Science ®Google Scholar
• He Y, Zuo C, Jia D, et al. Loss of DP1 aggravates vascular remodeling in pulmonary arterial hypertension via mTORC1 signaling. Am J Respir Crit Care Med. 2020;201(10):1263–1276. doi:10.1164/rccm.201911-2137OC
   PubMed Web of Science ®Google Scholar
• Hosokawa S, Haraguchi G, Sasaki A, et al. Pathophysiological roles of nuclear factor kappaB (NF-kB) in pulmonary arterial hypertension: effects of synthetic selective NF-kB inhibitor IMD-0354. Cardiovasc Res. 2013;99(1):35–43. doi:10.1093/cvr/cvt105
   PubMed Web of Science ®Google Scholar